Merck asserts patent infringement claims under Hatch-Waxman Act relating to Bridion® against 16 generic drug makers
Clients Merck & Co., Inc.
Jones Day is representing Merck & Co., Inc. in Hatch-Waxman patent infringement actions against 16 generic drug maker defendant groups, relating to the defendant groups' submissions of Abbreviated New Drug Applications to the FDA seeking approval of generic versions of Bridion®, a first-in-class agent for the reversal of certain types of neuromuscular blockade in adults undergoing surgery.
In re Sugammadex, No. 2-20-cv-02576 (CCC) (MF) (consolidated) (D.N.J.)